Probable Genitourinary Adverse Events Associated With Atomoxetine in an Adult Male: A Case Report

Ian R. McGrane, Trevor J. Campbell

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Atomoxetine is a norepinephrine reuptake inhibitor used for treatment of attention-deficit/hyperactivity disorder. Prescribing information from the manufacturer lists genitourinary-related adverse events such as urinary hesitancy/retention and priapism as precautions for atomoxetine. We report a case of urinary hesitancy with milky, white-colored discharge associated with atomoxetine use in a 42-year-old male. The onset of genitourinary symptoms occurred within 2 days of atomoxetine 40 mg daily initiation. Laboratories, urinalysis, sexually transmitted infection analysis, and genital examinations were all unremarkable. Within 2 days of atomoxetine discontinuation, the genitourinary symptoms were no longer present. We calculated a Naranjo adverse event score of 5, indicating atomoxetine probably caused the genitourinary adverse events. A review of literature suggests that urine outflow obstruction-related adverse events occur more commonly in men compared to women. Discontinuation of atomoxetine appears to lead to rapid resolution of the adverse events. Additionally, spontaneous ejaculation and sexual side effects rarely occur with atomoxetine. Clinicians should educate and monitor patients explicitly for genitourinary-related adverse events, as they may not be spontaneously reported.

Original languageEnglish
Pages (from-to)962-965
Number of pages4
JournalJournal of Pharmacy Practice
Issue number6
StatePublished - Dec 2021


  • atomoxetine
  • ejaculation
  • genitourinary
  • urinary hesitancy
  • urinary retention


Dive into the research topics of 'Probable Genitourinary Adverse Events Associated With Atomoxetine in an Adult Male: A Case Report'. Together they form a unique fingerprint.

Cite this